1
|
Silva AR, Ayuso M, García PA, Barros L, Edrada-Ebel R. Unveiling the metabolites underlying the skin anti-ageing properties of Cytinus hypocistis (L.) L. through a biochemometric approach. PHYTOMEDICINE : INTERNATIONAL JOURNAL OF PHYTOTHERAPY AND PHYTOPHARMACOLOGY 2024; 129:155685. [PMID: 38696922 DOI: 10.1016/j.phymed.2024.155685] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/24/2023] [Revised: 03/01/2024] [Accepted: 04/24/2024] [Indexed: 05/04/2024]
Abstract
BACKGROUND The genus Cytinus, recognised as one of the most enigmatic in the plant kingdom, has garnered attention for its bioactive potential, particularly its skin anti-ageing properties. Despite this recognition, much remains to be accomplished regarding deciphering and isolating its most active compounds. HYPOTHESIS This study aimed to identify the compounds responsible for C. hypocistis skin anti-ageing potential. METHODS Using multivariate analysis, a biochemometric approach was applied to identify the discriminant metabolites by integrating extracts' chemical profile (Liquid Chromatography-High-Resolution Mass Spectrometry, LCHRMS) and bioactive properties. The identified bioactive metabolite was structurally elucidated by 1D and 2D Nuclear Magnetic Resonance (NMR). RESULTS Among the studied bioactivities, the anti-elastase results exhibited a significant variation among the samples from different years. After the biochemometric analysis, the compound 2,3:4,6-bis(hexahydroxydiphenoyl)glucose, with a molecular mass of 784.075 Da, was structurally elucidated as the discriminant feature responsible for the outstanding human neutrophil elastase inhibition. Remarkably, the subfraction containing this compound exhibited a tenfold improvement in neutrophil elastase inhibition efficacy compared to the crude extract; its effectiveness fell within the same range as SPCK, a potent irreversible neutrophil elastase inhibitor. Moreover, this subfraction displayed no cytotoxicity or phototoxicity and excellent efficacy for the tested anti-ageing properties. CONCLUSIONS Hydrolysable tannins were confirmed as the metabolites behind C. hypocistis skin anti-ageing properties, effectively mitigating critical molecular mechanisms that influence the phenotypically distinct ageing clinical manifestations. Pedunculagin was particularly effective in inhibiting neutrophil elastase, considered one of the most destructive enzymes in skin ageing.
Collapse
Affiliation(s)
- Ana Rita Silva
- Centro de Investigação de Montanha (CIMO), Instituto Politécnico de Bragança, Campus de Santa Apolónia, 5300-253 Bragança, Portugal; Laboratório Associado para a Sustentabilidade e Tecnologia em Regiões de Montanha (SusTEC), Instituto Politécnico de Bragança, Campus de Santa Apolónia, 5300-253 Bragança, Portugal; Departamento de Ciencias Farmacéuticas. Facultad de Farmacia, CIETUS-IBSAL, Universidad de Salamanca, 37007 Salamanca, España; Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, The John Arbuthnott Building, 161 Cathedral Street, Glasgow G4 0RE, United Kingdom.
| | - Manuel Ayuso
- Centro de Investigação de Montanha (CIMO), Instituto Politécnico de Bragança, Campus de Santa Apolónia, 5300-253 Bragança, Portugal; Laboratório Associado para a Sustentabilidade e Tecnologia em Regiões de Montanha (SusTEC), Instituto Politécnico de Bragança, Campus de Santa Apolónia, 5300-253 Bragança, Portugal
| | - Pablo A García
- Departamento de Ciencias Farmacéuticas. Facultad de Farmacia, CIETUS-IBSAL, Universidad de Salamanca, 37007 Salamanca, España
| | - Lillian Barros
- Centro de Investigação de Montanha (CIMO), Instituto Politécnico de Bragança, Campus de Santa Apolónia, 5300-253 Bragança, Portugal; Laboratório Associado para a Sustentabilidade e Tecnologia em Regiões de Montanha (SusTEC), Instituto Politécnico de Bragança, Campus de Santa Apolónia, 5300-253 Bragança, Portugal
| | - RuAngelie Edrada-Ebel
- Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, The John Arbuthnott Building, 161 Cathedral Street, Glasgow G4 0RE, United Kingdom.
| |
Collapse
|
2
|
Vachiramon V, Sakpuwadol N, Yongpisarn T, Anuntrangsee T, Palakornkitti P. Efficacy of isobutylamido thiazolyl resorcinol for prevention of laser-induced post-inflammatory hyperpigmentation: A randomized, controlled trial. J Cosmet Dermatol 2024; 23:2450-2457. [PMID: 38497328 DOI: 10.1111/jocd.16287] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2023] [Revised: 02/29/2024] [Accepted: 03/06/2024] [Indexed: 03/19/2024]
Abstract
BACKGROUND Q-switched (QS) Nd: YAG laser is one of the treatment options for solar lentigines (SLs). However, the incidence of post-inflammatory hyperpigmentation (PIH) is a common complication, especially in dark-complexioned skin. Isobutylamido thiazolyl resorcinol (ITR) has been reported as a preventive modality for ultraviolet B (UVB)-induced hyperpigmentation. AIMS This study aims to evaluate the efficacy and safety of ITR for the prevention of laser-induced PIH. PATIENTS/METHODS A randomized, evaluator-blinded study including 24 subjects with SLs was conducted. Three SLs of each patient were randomized into three groups, which were to apply ITR twice daily, once daily, and no application for 2 weeks. Thereafter, 532-nm QS Nd: YAG laser was performed. Incidence of laser-induced PIH, relative melanin index (RMI), mean luminance score (L*), hyperpigmentation score, and adverse events were recorded for 2 months post-laser. RESULTS The incidence of PIH at the 4th week after laser treatment was significantly lower in the ITR twice-daily group compared to the no-application group (20.83% vs. 50%, p = 0.028). There was no statistically significant difference in RMI, mean L*, and hyperpigmentation score between treatments at all visits. No serious adverse events were reported regarding ITR application and laser treatment. CONCLUSION Two-week application of ITR prior to QS: Nd YAG laser treatment may potentially reduce the incidence of PIH. A longer duration of application, including after the laser procedure, may be more beneficial for the prevention of laser-induced PIH.
Collapse
Affiliation(s)
- Vasanop Vachiramon
- Division of Dermatology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
| | - Nawara Sakpuwadol
- Division of Dermatology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
| | - Tanat Yongpisarn
- Division of Dermatology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
| | - Tanaporn Anuntrangsee
- Division of Dermatology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
| | - Pasita Palakornkitti
- Division of Dermatology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
| |
Collapse
|
3
|
Lazinski LM, Beaumet M, Roulier B, Gay R, Royal G, Maresca M, Haudecoeur R. Design and synthesis of 4-amino-2',4'-dihydroxyindanone derivatives as potent inhibitors of tyrosinase and melanin biosynthesis in human melanoma cells. Eur J Med Chem 2024; 266:116165. [PMID: 38262119 DOI: 10.1016/j.ejmech.2024.116165] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2023] [Revised: 01/16/2024] [Accepted: 01/18/2024] [Indexed: 01/25/2024]
Abstract
Melanogenesis inhibition constitutes a privileged therapeutic solution to treat skin hyperpigmentation, a major dermatological concern associated with the overproduction of melanin by human tyrosinase (hsTYR). Despite the existence of many well-known TYR (tyrosinase) inhibitors commercialized in skin formulations, their hsTYR-inhibition efficacy remains poor since most of them were investigated over mushroom tyrosinase (abTYR), a model with low homology relative to hsTYR. Considering the need for new potent hsTYR inhibitors, we designed and synthesized a series of indanones starting from 4-hydroxy compound 1a, one of the two most active derivatives reported to date against the human enzyme, together with marketed thiamidol. We observed that analogues featuring 4-amino and 4-amido-2',4'-dihydroxyindanone motifs showed two-to ten-fold increase in activity over human melanoma MNT-1 cell lysates, and a ten-fold improvement in a 4-days whole-cell experiment, compared to parent analogue 1a. Molecular docking investigation was performed for the most promising 4-amido derivatives and suggested a plausible interaction pattern with the second coordination sphere of hsTYR, notably through hydrogen bonding with Glu203, confirming their impact in the binding mode with hsTYR active site.
Collapse
Affiliation(s)
- Leticia M Lazinski
- Univ. Grenoble Alpes, CNRS, DPM, 38000, Grenoble, France; Univ. Grenoble Alpes, CNRS, DCM, 38000, Grenoble, France
| | - Morane Beaumet
- Univ. Grenoble Alpes, CNRS, DPM, 38000, Grenoble, France
| | - Brayan Roulier
- Univ. Grenoble Alpes, CNRS, DPM, 38000, Grenoble, France
| | - Rémy Gay
- Univ. Grenoble Alpes, CNRS, DPM, 38000, Grenoble, France
| | - Guy Royal
- Univ. Grenoble Alpes, CNRS, DCM, 38000, Grenoble, France
| | - Marc Maresca
- Aix Marseille Univ., CNRS, Centrale Marseille, iSm2, 13013, Marseille, France
| | | |
Collapse
|
4
|
Mizuno-Kaneko M, Hashimoto I, Miyahara K, Kochi M, Ohashi N, Tsumura K, Suzuki K, Tamura T. Molecular Design of Cyclic Peptides with Cell Membrane Permeability and Development of MDMX-p53 Inhibitor. ACS Med Chem Lett 2023; 14:1174-1178. [PMID: 37736191 PMCID: PMC10510666 DOI: 10.1021/acsmedchemlett.3c00102] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2023] [Accepted: 08/07/2023] [Indexed: 09/23/2023] Open
Abstract
Cyclic peptides have been expected to be one of the modalities of intracellular protein-protein interaction (PPI) inhibitors, but they are generally known to have low cell membrane permeability. In this study, we focused on the conformation of cyclic peptides in the cell membrane to determine the requirement for their cell membrane permeability through passive diffusion. Utilizing the requirement, we searched for structures with high affinity for MDMX via computational chemistry and acquired cyclic peptide 19 (Papp = 0.80 × 10-6 cm s-1, IC50 = 0.07 μM).
Collapse
Affiliation(s)
- Mai Mizuno-Kaneko
- Synthetic
Organic Chemistry Laboratories, FUJIFILM
Corporation, 577, Ushijima, Kaisei-machi, Ashigarakami-gun, Kanagawa 258-8577, Japan
| | - Ichihiko Hashimoto
- Analysis
Technology Center, FUJIFILM Corporation, 210, Nakanuma, Minamiashigara-shi, Kanagawa 250-0193, Japan
| | - Kenta Miyahara
- Analysis
Technology Center, FUJIFILM Corporation, 210, Nakanuma, Minamiashigara-shi, Kanagawa 250-0193, Japan
| | - Masahiro Kochi
- Analysis
Technology Center, FUJIFILM Corporation, 210, Nakanuma, Minamiashigara-shi, Kanagawa 250-0193, Japan
| | - Noriyuki Ohashi
- Analysis
Technology Center, FUJIFILM Corporation, 210, Nakanuma, Minamiashigara-shi, Kanagawa 250-0193, Japan
| | - Kyosuke Tsumura
- Analysis
Technology Center, FUJIFILM Corporation, 210, Nakanuma, Minamiashigara-shi, Kanagawa 250-0193, Japan
| | - Koo Suzuki
- Analysis
Technology Center, FUJIFILM Corporation, 210, Nakanuma, Minamiashigara-shi, Kanagawa 250-0193, Japan
| | - Takashi Tamura
- Synthetic
Organic Chemistry Laboratories, FUJIFILM
Corporation, 577, Ushijima, Kaisei-machi, Ashigarakami-gun, Kanagawa 258-8577, Japan
| |
Collapse
|
5
|
Veerichetty V, Saravanabavan I. Molecular docking Study of Nuciferine as a Tyrosinase Inhibitor and Its Therapeutic Potential for Hyperpigmentation. Genomics Inform 2023; 21:e43. [PMID: 37813639 PMCID: PMC10584639 DOI: 10.5808/gi.23054] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2023] [Revised: 08/28/2023] [Accepted: 09/02/2023] [Indexed: 10/11/2023] Open
Abstract
Melanin is synthesized by tyrosinase to protect the skin from ultraviolet light. However, overproduction and accumulation of melanin can result in hyperpigmentation and skin melanoma. Tyrosinase inhibitors are commonly used in the treatment of hyperpigmentation. Natural tyrosinase inhibitors are often favored over synthetic ones due to the potential side effects of the latter, which can include skin irritation, allergies, and other adverse reactions. Nuciferine, an alkaloid derived from Nelumbo nucifera, exhibits potent antioxidant and anti-proliferative properties. This study focused on the in silico screening of nuciferine for anti-tyrosinase activity, using kojic acid, ascorbic acid, and resorcinol as standards. The tyrosinase protein target was selected through homology modeling. The residues of the substrate binding pocket and active site pockets were identified for the purposes of grid box optimization and docking. Nuciferine demonstrated a binding energy of -7.0 kcal/mol and a Ki of 5 µM, both of which were comparatively higher than the corresponding values of kojic acid, which showed -5.3 kcal/mol and 122 µM respectively. Therefore, nuciferine is a potent natural tyrosinase inhibitor and shows promising potential for application in the treatment of hyperpigmentation and skin melanoma.
Collapse
Affiliation(s)
- Veerabhuvaneshwari Veerichetty
- Department of Biotechnology, Kumaraguru College of Technology affiliated with Anna University, Coimbatore, Tamil Nadu 641006, India
| | - Iswaryalakshmi Saravanabavan
- Department of Biotechnology, Kumaraguru College of Technology affiliated with Anna University, Coimbatore, Tamil Nadu 641006, India
| |
Collapse
|
6
|
Vittorio S, Dank C, Ielo L. Heterocyclic Compounds as Synthetic Tyrosinase Inhibitors: Recent Advances. Int J Mol Sci 2023; 24:ijms24109097. [PMID: 37240442 DOI: 10.3390/ijms24109097] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2023] [Revised: 05/19/2023] [Accepted: 05/20/2023] [Indexed: 05/28/2023] Open
Abstract
Tyrosinase is a copper-containing enzyme which is widely distributed in nature (e.g., bacteria, mammals, fungi) and involved in two consecutive steps of melanin biosynthesis. In humans, an excessive production of melanin can determine hyperpigmentation disorders as well as neurodegenerative processes in Parkinson's disease. The development of molecules able to inhibit the high activity of the enzyme remain a current topic in medicinal chemistry, because the inhibitors reported so far present several side effects. Heterocycle-bearing molecules are largely diffuse in this sense. Due to their importance as biologically active compounds, we decided to report a comprehensive review of synthetic tyrosinase inhibitors possessing heterocyclic moieties reported within the last five years. For the reader's convenience, we classified them as inhibitors of mushroom tyrosinase (Agaricus bisporus) and human tyrosinase.
Collapse
Affiliation(s)
- Serena Vittorio
- Dipartimento di Scienze Farmaceutiche, Università degli Studi di Milano, Via Mangiagalli, 25, 20133 Milano, Italy
| | - Christian Dank
- Institute of Organic Chemistry, University of Vienna, Währinger Strasse 38, 1090 Vienna, Austria
| | - Laura Ielo
- Department of Chemistry, University of Turin, Via P. Giuria 7, 10125 Torino, Italy
| |
Collapse
|
7
|
Zolghadri S, Beygi M, Mohammad TF, Alijanianzadeh M, Pillaiyar T, Garcia-Molina P, Garcia-Canovas F, Luis Munoz-Munoz J, Akbar Saboury A. Targeting Tyrosinase in Hyperpigmentation: Current Status, Limitations and Future Promises. Biochem Pharmacol 2023; 212:115574. [PMID: 37127249 DOI: 10.1016/j.bcp.2023.115574] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2023] [Revised: 04/21/2023] [Accepted: 04/24/2023] [Indexed: 05/03/2023]
Abstract
Hyperpigmentation is a common and distressing dermatologic condition. Since tyrosinase (TYR) plays an essential role in melanogenesis, its inhibition is considered a logical approach along with other therapeutic methods to prevent the accumulation of melanin in the skin. Thus, TYR inhibitors are a tempting target as the medicinal and cosmetic active agents of hyperpigmentation disorder. Among TYR inhibitors, hydroquinone is a traditional lightening agent that is commonly used in clinical practice. However, despite good efficacy, prolonged use of hydroquinone is associated with side effects. To overcome these shortcomings, new approaches in targeting TYR and treating hyperpigmentation are desperately requiredessentialneeded. In line with this purpose, several non-hydroquinone lightening agents have been developed and suggested as hydroquinone alternatives. In addition to traditional approaches, nanomedicine and nanotheranostic platforms have been recently proposed in the treatment of hyperpigmentation. In this review, we discuss the available strategies for the management of hyperpigmentation with a focus on TYR inhibition. In addition, alternative treatment options to hydroquinone are discussed. Finally, we present nano-based strategies to improve the therapeutic effect of drugs prescribed to patients with skin disorders.
Collapse
Affiliation(s)
- Samaneh Zolghadri
- Department of Biology, Jahrom Branch, Islamic Azad University, Jahrom, Iran.
| | - Mohammad Beygi
- Department of Agricultural Biotechnology, College of Agriculture, Isfahan University of Technology, Isfahan, Iran
| | | | - Mahdi Alijanianzadeh
- Department of Cell & Molecular Biology, Faculty of Biological Sciences, Kharazmi University, Tehran, Iran
| | - Thanigaimalai Pillaiyar
- Institute of Pharmacy, Pharmaceutical/Medicinal Chemistry and Tuebingen Center for Academic Drug Discovery, Eberhard Karls University Tübingen, Auf der Morgenstelle 8, 72076 Tübingen, Germany
| | - Pablo Garcia-Molina
- GENZ-Group of Research on Enzymology, Department of Biochemistry and Molecular Biology-A, Regional Campus of International Excellence "Campus Mare Nostrum", University of Murcia, Espinardo, Murcia, Spain
| | - Francisco Garcia-Canovas
- GENZ-Group of Research on Enzymology, Department of Biochemistry and Molecular Biology-A, Regional Campus of International Excellence "Campus Mare Nostrum", University of Murcia, Espinardo, Murcia, Spain
| | - Jose Luis Munoz-Munoz
- Microbial Enzymology Lab, Department of Applied Sciences, Ellison Building A, University of Northumbria, Newcastle Upon Tyne, UK
| | - Ali Akbar Saboury
- Institute of Biochemistry and Biophysics, University of Tehran, Tehran, Iran.
| |
Collapse
|
8
|
Roulier B, Rush I, Lazinski LM, Pérès B, Olleik H, Royal G, Fishman A, Maresca M, Haudecoeur R. Resorcinol-based hemiindigoid derivatives as human tyrosinase inhibitors and melanogenesis suppressors in human melanoma cells. Eur J Med Chem 2023; 246:114972. [PMID: 36462443 DOI: 10.1016/j.ejmech.2022.114972] [Citation(s) in RCA: 10] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2022] [Revised: 11/24/2022] [Accepted: 11/24/2022] [Indexed: 11/29/2022]
Abstract
Human tyrosinase (hsTYR) catalyzes the key steps of melanogenesis, making it a privileged target for reducing melanin production in vivo. However, very few hsTYR inhibitors have been reported so far in the literature, whereas thousands of mushroom tyrosinase (abTYR) inhibitors are known. Yet, as these enzymes are actually very different, including at their active sites, there is an urgent need for new true hsTYR inhibitors in order to enable human-directed pharmacological and dermocosmetic applications without encountering the inefficiency and toxicity issues currently triggered by kojic acid or hydroquinone. Starting from the two most active compounds reported to date, i.e. a 2-hydroxypyridine-embedded aurone and thiamidol, we combined herein key structural elements and developed new nanomolar hsTYR inhibitors with cell-based activity. From a complete series of thirty-eight synthesized derivatives, excellent inhibition values were obtained for two compounds in both human melanoma cell lysates and purified hsTYR assays, and a promising improvement was observed in whole cell experiments.
Collapse
Affiliation(s)
- Brayan Roulier
- Univ. Grenoble Alpes, CNRS 5063, DPM, 38000, Grenoble, France
| | - Inbal Rush
- Department of Biotechnology and Food Engineering, Technion - Israel Institute of Technology, Haifa, 3200003, Israel
| | - Leticia M Lazinski
- Univ. Grenoble Alpes, CNRS 5063, DPM, 38000, Grenoble, France; Univ. Grenoble Alpes, CNRS 5250, DCM, 38000, Grenoble, France
| | - Basile Pérès
- Univ. Grenoble Alpes, CNRS 5063, DPM, 38000, Grenoble, France
| | - Hamza Olleik
- Aix Marseille Univ., CNRS, Centrale Marseille, iSm2, 13397, Marseille, France
| | - Guy Royal
- Univ. Grenoble Alpes, CNRS 5250, DCM, 38000, Grenoble, France
| | - Ayelet Fishman
- Department of Biotechnology and Food Engineering, Technion - Israel Institute of Technology, Haifa, 3200003, Israel
| | - Marc Maresca
- Aix Marseille Univ., CNRS, Centrale Marseille, iSm2, 13397, Marseille, France
| | | |
Collapse
|
9
|
Ghani U. Azole inhibitors of mushroom and human tyrosinases: Current advances and prospects of drug development for melanogenic dermatological disorders. Eur J Med Chem 2022; 239:114525. [PMID: 35717871 DOI: 10.1016/j.ejmech.2022.114525] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2022] [Revised: 06/05/2022] [Accepted: 06/06/2022] [Indexed: 11/16/2022]
Abstract
Azoles are a famous and promising class of drugs for treatment of a range of ailments especially fungal infections. A wide variety of azole derivatives are also known to exhibit tyrosinase inhibition, some of which possess promising activity with potential for treatment of dermatological disorders such as post-inflammatory hyperpigmentation, nevus, flecks, melasma, and melanoma. Recently, thiazolyl-resorcinol derivatives have demonstrated potent human tyrosinase inhibition with a safe and effective therapeutic profile for treatment of skin hyperpigmentation in humans, which are currently under clinical trials. If approved these derivatives would be the first azole drugs to be used for treatment of skin hyperpigmentation. Although the scientific literature has been witnessing general reviews on tyrosinase inhibitors to date, there is none that specifically and comprehensively discusses azole inhibitors of tyrosinase. Appreciating such potential of azoles, this focused review highlights a wide range of their derivatives with promising mushroom and human tyrosinase inhibitory activities and clinical potential for treatment of melanogenic dermatological disorders. Presently, these disorders have been treated with kojic acid, hydroquinone and other drugs, the design and development of which are based on their ability to inhibit mushroom tyrosinase. The active sites of mushroom and human tyrosinases carry structural differences which affect substrate or inhibitor binding. For this reason, kojic acid and other drugs pose efficacy and safety issues since they were originally developed using mushroom tyrosinase and have been clinically used on human tyrosinase. Design and development of tyrosinase inhibitors should be based on human tyrosinase, however, there are challenges in obtaining the human enzyme and understanding its structure and function. The review discusses these challenges that encompass structural and functional differences between mushroom and human tyrosinases and the manner in which they are inhibited. The review also gauges promising azole derivatives with potential for development of drugs against skin hyperpigmentation by analyzing and comparing their tyrosinase inhibitory activities against mushroom and human tyrosinases, computational data, and clinical profile where available. It aims to lay groundwork for development of new azole drugs for treatment of skin hyperpigmentation, melanoma, and related dermatological disorders.
Collapse
Affiliation(s)
- Usman Ghani
- Clinical Biochemistry Unit, Department of Pathology, College of Medicine, King Saud University, Riyadh, 12372, Saudi Arabia.
| |
Collapse
|
10
|
Krzemińska A, Kwiatos N, Arenhart Soares F, Steinbüchel A. Theoretical Studies of Cyanophycin Dipeptides as Inhibitors of Tyrosinases. Int J Mol Sci 2022; 23:ijms23063335. [PMID: 35328756 PMCID: PMC8950311 DOI: 10.3390/ijms23063335] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2022] [Revised: 03/13/2022] [Accepted: 03/17/2022] [Indexed: 02/06/2023] Open
Abstract
The three-dimensional structure of tyrosinase has been crystallized from many species but not from Homo sapiens. Tyrosinase is a key enzyme in melanin biosynthesis, being an important target for melanoma and skin-whitening cosmetics. Several studies employed the structure of tyrosinase from Agaricus bisporus as a model enzyme. Recently, 98% of human genome proteins were elucidated by AlphaFold. Herein, the AlphaFold structure of human tyrosinase and the previous model were compared. Moreover, tyrosinase-related proteins 1 and 2 were included, along with inhibition studies employing kojic and cinnamic acids. Peptides are widely studied for their inhibitory activity of skin-related enzymes. Cyanophycin is an amino acid polymer produced by cyanobacteria and is built of aspartic acid and arginine; arginine can be also replaced by other amino acids. A new set of cyanophycin-derived dipeptides was evaluated as potential inhibitors. Aspartate–glutamate showed the strongest interaction and was chosen as a leading compound for future studies.
Collapse
|
11
|
Choi H, Young Ryu I, Choi I, Ullah S, Jin Jung H, Park Y, Hwang Y, Jeong Y, Hong S, Chun P, Young Chung H, Ryong Moon H. Identification of (Z)-2-benzylidene-dihydroimidazothiazolone derivatives as tyrosinase inhibitors: anti-melanogenic effects and in silico studies. Comput Struct Biotechnol J 2022; 20:899-912. [PMID: 35242283 PMCID: PMC8861568 DOI: 10.1016/j.csbj.2022.02.007] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2021] [Revised: 02/09/2022] [Accepted: 02/10/2022] [Indexed: 12/19/2022] Open
Affiliation(s)
- Heejeong Choi
- College of Pharmacy, Pusan National University, Busan 46241, South Korea
| | - Il Young Ryu
- College of Pharmacy, Pusan National University, Busan 46241, South Korea
| | - Inkyu Choi
- College of Pharmacy, Pusan National University, Busan 46241, South Korea
| | - Sultan Ullah
- Department of Molecular Medicine, The Scripps Research Institute, FL 33458, USA
| | - Hee Jin Jung
- College of Pharmacy, Pusan National University, Busan 46241, South Korea
| | - Yujin Park
- College of Pharmacy, Pusan National University, Busan 46241, South Korea
| | - YeJi Hwang
- College of Pharmacy, Pusan National University, Busan 46241, South Korea
| | - Yeongmu Jeong
- College of Pharmacy, Pusan National University, Busan 46241, South Korea
| | - Sojeong Hong
- College of Pharmacy, Pusan National University, Busan 46241, South Korea
| | - Pusoon Chun
- College of Pharmacy and Inje Institute of Pharmaceutical Sciences and Research, Inje University, Gimhae, Gyeongnam 50834, South Korea
| | - Hae Young Chung
- College of Pharmacy, Pusan National University, Busan 46241, South Korea
| | - Hyung Ryong Moon
- College of Pharmacy, Pusan National University, Busan 46241, South Korea
- Corresponding author at: Laboratory of Medicinal Chemistry, College of Pharmacy, Pusan National University, Busan 46241, South Korea.
| |
Collapse
|
12
|
Roggenkamp D, Sammain A, Fürstenau M, Kausch M, Passeron T, Kolbe L. Thiamidol ® in moderate-to-severe melasma: 24-week, randomized, double-blind, vehicle-controlled clinical study with subsequent regression phase. J Dermatol 2021; 48:1871-1876. [PMID: 34676600 DOI: 10.1111/1346-8138.16080] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2021] [Revised: 06/25/2021] [Accepted: 07/11/2021] [Indexed: 11/26/2022]
Abstract
Thiamidol® was the most potent inhibitor of human tyrosinase out of 50 000 screened substances. In vivo, it was well tolerated and improved melasma significantly. This was the first 24-week, randomized, double-blind, vehicle-controlled, cosmetic clinical study to assess the efficacy and tolerability of thiamidol in moderate-to-severe melasma of phototype III-V subjects with subsequent regression phase. Females allocated to verum (n = 23), applied daily Dual Serum followed either by Day Care SPF30 in the morning or by Night Care in the evening, all containing Thiamidol. The vehicle group (25 females) followed the same skin care routine using the corresponding vehicle formulations. Subjects came back for a follow-up visit 13-20 weeks after treatment (regression phase). Assessments included clinical photography, Melasma Area and Severity Index (MASI), skin lightness, quality of life, and tolerability. Baseline demographics and hyperpigmentation were well balanced across the treatment groups. Clinical photography and MASI improved with Thiamidol significantly versus baseline (p < 0.001) and vehicle (p < 0.001-0.043) at all time points up to treatment end. At follow-up, the MASI was still significantly lower than at baseline but similar for verum and vehicle. Skin lightness and quality of life improved significantly versus baseline without significant differences between verum and vehicle. This study demonstrated that Thiamidol is well tolerated and superior in improving melasma compared to baseline and vehicle over a treatment period of 24 weeks.
Collapse
Affiliation(s)
| | - Adel Sammain
- International Medical Management, Beiersdorf AG, Hamburg, Germany
| | | | | | - Thierry Passeron
- Centre Méditerranéen de Médecine Moléculaire - C3M, University Côte d'Azur, INSERM U1065, Nice, France.,Department of Dermatology, University Côte d'Azur, CHU Nice, Nice, France
| | - Ludger Kolbe
- Research & Development, Beiersdorf AG, Hamburg, Germany
| |
Collapse
|
13
|
Mirabile S, Vittorio S, Paola Germanò M, Adornato I, Ielo L, Rapisarda A, Gitto R, Pintus F, Fais A, De Luca L. Evaluation of 4-(4-Fluorobenzyl)piperazin-1-yl]-Based Compounds as Competitive Tyrosinase Inhibitors Endowed with Antimelanogenic Effects. ChemMedChem 2021; 16:3083-3093. [PMID: 34223697 PMCID: PMC8518915 DOI: 10.1002/cmdc.202100396] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2021] [Revised: 07/02/2021] [Indexed: 11/11/2022]
Abstract
There is a considerable attention for the development of inhibitors of tyrosinase (TYR) as therapeutic strategy for the treatment of hyperpigmentation disorders in humans. Continuing in our efforts to identify TYR inhibitors, we describe the design, synthesis and pharmacophore exploration of new small molecules structurally characterized by the presence of the 4-fluorobenzylpiperazine moiety as key pharmacophoric feature for the inhibition of TYR from Agaricus bisporus (AbTYR). Our investigations resulted in the discovery of the competitive inhibitor [4-(4-fluorobenzyl)piperazin-1-yl]-(3-chloro-2-nitro-phenyl)methanone 26 (IC50 =0.18 μM) that proved to be ∼100-fold more active than reference compound kojic acid (IC50 =17.76 μM). Notably, compound 26 exerted antimelanogenic effect on B16F10 cells in absence of cytotoxicity. Docking analysis suggested its binding mode into AbTYR and into modelled human TYR.
Collapse
Affiliation(s)
- Salvatore Mirabile
- Department of ChemicalBiological, Pharmaceutical and Environmental SciencesUniversity of MessinaViale Palatucci 1398168MessinaItaly
| | - Serena Vittorio
- Department of ChemicalBiological, Pharmaceutical and Environmental SciencesUniversity of MessinaViale Palatucci 1398168MessinaItaly
| | - Maria Paola Germanò
- Department of ChemicalBiological, Pharmaceutical and Environmental SciencesUniversity of MessinaViale Palatucci 1398168MessinaItaly
| | - Ilenia Adornato
- Department of ChemicalBiological, Pharmaceutical and Environmental SciencesUniversity of MessinaViale Palatucci 1398168MessinaItaly
| | - Laura Ielo
- Department of ChemistryUniversity of TurinVia P. Giuria 710125TurinItaly
| | - Antonio Rapisarda
- Department of ChemicalBiological, Pharmaceutical and Environmental SciencesUniversity of MessinaViale Palatucci 1398168MessinaItaly
| | - Rosaria Gitto
- Department of ChemicalBiological, Pharmaceutical and Environmental SciencesUniversity of MessinaViale Palatucci 1398168MessinaItaly
| | - Francesca Pintus
- Department of Life and Environment SciencesUniversity of Cagliari09042MonserratoCagliariItaly
| | - Antonella Fais
- Department of Life and Environment SciencesUniversity of Cagliari09042MonserratoCagliariItaly
| | - Laura De Luca
- Department of ChemicalBiological, Pharmaceutical and Environmental SciencesUniversity of MessinaViale Palatucci 1398168MessinaItaly
| |
Collapse
|
14
|
Fan YF, Zhu SX, Hou FB, Zhao DF, Pan QS, Xiang YW, Qian XK, Ge GB, Wang P. Spectrophotometric Assays for Sensing Tyrosinase Activity and Their Applications. BIOSENSORS 2021; 11:290. [PMID: 34436092 PMCID: PMC8393227 DOI: 10.3390/bios11080290] [Citation(s) in RCA: 19] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/09/2021] [Revised: 08/17/2021] [Accepted: 08/19/2021] [Indexed: 12/13/2022]
Abstract
Tyrosinase (TYR, E.C. 1.14.18.1), a critical enzyme participating in melanogenesis, catalyzes the first two steps in melanin biosynthesis including the ortho-hydroxylation of L-tyrosine and the oxidation of L-DOPA. Previous pharmacological investigations have revealed that an abnormal level of TYR is tightly associated with various dermatoses, including albinism, age spots, and malignant melanoma. TYR inhibitors can partially block the formation of pigment, which are always used for improving skin tone and treating dermatoses. The practical and reliable assays for monitoring TYR activity levels are very useful for both disease diagnosis and drug discovery. This review comprehensively summarizes structural and enzymatic characteristics, catalytic mechanism and substrate preference of TYR, as well as the recent advances in biochemical assays for sensing TYR activity and their biomedical applications. The design strategies of various TYR substrates, alongside with several lists of all reported biochemical assays for sensing TYR including analytical conditions and kinetic parameters, are presented for the first time. Additionally, the biomedical applications and future perspectives of these optical assays are also highlighted. The information and knowledge presented in this review offer a group of practical and reliable assays and imaging tools for sensing TYR activities in complex biological systems, which strongly facilitates high-throughput screening TYR inhibitors and further investigations on the relevance of TYR to human diseases.
Collapse
Affiliation(s)
- Yu-Fan Fan
- Shanghai Frontiers Science Center for Chinese Medicine Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China; (Y.-F.F.); (F.-B.H.); (D.-F.Z.); (Q.-S.P.); (X.-K.Q.); (G.-B.G.)
| | - Si-Xing Zhu
- Institute of Science, Technology and Humanities, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China;
| | - Fan-Bin Hou
- Shanghai Frontiers Science Center for Chinese Medicine Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China; (Y.-F.F.); (F.-B.H.); (D.-F.Z.); (Q.-S.P.); (X.-K.Q.); (G.-B.G.)
| | - Dong-Fang Zhao
- Shanghai Frontiers Science Center for Chinese Medicine Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China; (Y.-F.F.); (F.-B.H.); (D.-F.Z.); (Q.-S.P.); (X.-K.Q.); (G.-B.G.)
| | - Qiu-Sha Pan
- Shanghai Frontiers Science Center for Chinese Medicine Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China; (Y.-F.F.); (F.-B.H.); (D.-F.Z.); (Q.-S.P.); (X.-K.Q.); (G.-B.G.)
| | - Yan-Wei Xiang
- School of Rehabilitation Science, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China;
| | - Xing-Kai Qian
- Shanghai Frontiers Science Center for Chinese Medicine Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China; (Y.-F.F.); (F.-B.H.); (D.-F.Z.); (Q.-S.P.); (X.-K.Q.); (G.-B.G.)
| | - Guang-Bo Ge
- Shanghai Frontiers Science Center for Chinese Medicine Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China; (Y.-F.F.); (F.-B.H.); (D.-F.Z.); (Q.-S.P.); (X.-K.Q.); (G.-B.G.)
| | - Ping Wang
- Shanghai Frontiers Science Center for Chinese Medicine Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China; (Y.-F.F.); (F.-B.H.); (D.-F.Z.); (Q.-S.P.); (X.-K.Q.); (G.-B.G.)
| |
Collapse
|
15
|
Taganov AV, Bragina AV. Keloid scars. Modern aspects of diagnosis and treatment. CONSILIUM MEDICUM 2021. [DOI: 10.26442/20751753.2021.8.201112] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Cicatricial skin hypertrophy includes keloids and hypertrophic scars. Keloid scarring is thought to result from an imbalance between increased synthesis of collagen and extracellular matrix and decreased degradation of these products. Current knowledge of keloid pathophysiology prompts clinicians to investigate new methods for the diagnosis and treatment of keloids, as well as their prevention.
Collapse
|
16
|
Recent advances in the design and discovery of synthetic tyrosinase inhibitors. Eur J Med Chem 2021; 224:113744. [PMID: 34365131 DOI: 10.1016/j.ejmech.2021.113744] [Citation(s) in RCA: 51] [Impact Index Per Article: 17.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2021] [Revised: 07/28/2021] [Accepted: 07/28/2021] [Indexed: 02/08/2023]
Abstract
Tyrosinase is a copper-containing metalloenzyme that is responsible for the rate-limiting catalytic step in the melanin biosynthesis and enzymatic browning. As a promising target, tyrosinase inhibitors can be used as skin whitening agents and food preservatives, thus having broad potential in the fields of food, cosmetics, agriculture and medicine. From 2015 to 2020, numerous synthetic inhibitors of tyrosinase have been developed to overcome the challenges of low efficacy and side effects. This review summarizes the enzyme structure and biological functions of tyrosinase and demonstrates the recent advances of synthetic tyrosinase inhibitors from the perspective of medicinal chemistry, providing a better understanding of the catalytic mechanisms and more effective tyrosinase inhibitors.
Collapse
|
17
|
Gao D, Kim JH, Kim CT, Jeong WS, Kim HM, Sim J, Kang JS. Evaluation of Anti-Melanogenesis Activity of Enriched Pueraria lobata Stem Extracts and Characterization of Its Phytochemical Components Using HPLC-PDA-ESI-MS/MS. Int J Mol Sci 2021; 22:ijms22158105. [PMID: 34360871 PMCID: PMC8348418 DOI: 10.3390/ijms22158105] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2021] [Revised: 07/23/2021] [Accepted: 07/27/2021] [Indexed: 12/20/2022] Open
Abstract
The root of Pueraria lobata (Willd.) is a widely used herbal medicine worldwide, whereas the stem of the plant is discarded or used as feed for livestock. To reuse and exploit the stem of P. lobata as a resource, we investigated its potential as a skin-whitening agent. We found that the developed, enriched P. lobata stem (PLS) extract significantly inhibited melanin production in the 3-isobutyl-1-methylxanthine-induced B16/F10 cells at a concentration of 50 μg/mL. To further confirm the mechanism of the antimelanogenic effect of the enriched PLS extracts, we examined the mRNA expression of tyrosinase, which was suppressed by the extracts. To standardize and implement effective quality control of the enriched PLS extracts, its major chemical constituents were identified by high-performance liquid chromatography-photodiode array-electrospray ionization-mass spectrometry. In total, 12 constituents were identified. In silico analysis showed that the main constituents, puerarin and daidzin, had excellent binding affinities for human tyrosinase. Collectively, our results suggest that the PLS extracts could be used as anti-pigmentation agents.
Collapse
Affiliation(s)
- Dan Gao
- College of Pharmacy, Chungnam National University, Daejeon 34134, Korea; (D.G.); (J.H.K.); (H.M.K.)
| | - Jin Hyeok Kim
- College of Pharmacy, Chungnam National University, Daejeon 34134, Korea; (D.G.); (J.H.K.); (H.M.K.)
| | | | | | - Hyung Min Kim
- College of Pharmacy, Chungnam National University, Daejeon 34134, Korea; (D.G.); (J.H.K.); (H.M.K.)
| | - Jaehoon Sim
- College of Pharmacy, Chungnam National University, Daejeon 34134, Korea; (D.G.); (J.H.K.); (H.M.K.)
- Correspondence: (J.S.); (J.S.K.); Tel.: +82-42-821-5938 (J.S.); +82-42-821-5928 (J.S.K.)
| | - Jong Seong Kang
- College of Pharmacy, Chungnam National University, Daejeon 34134, Korea; (D.G.); (J.H.K.); (H.M.K.)
- Correspondence: (J.S.); (J.S.K.); Tel.: +82-42-821-5938 (J.S.); +82-42-821-5928 (J.S.K.)
| |
Collapse
|
18
|
Philipp-Dormston WG, Vila Echagüe A, Pérez Damonte SH, Riedel J, Filbry A, Warnke K, Lofrano C, Roggenkamp D, Nippel G. Thiamidol containing treatment regimens in facial hyperpigmentation: An international multi-centre approach consisting of a double-blind, controlled, split-face study and of an open-label, real-world study. Int J Cosmet Sci 2021; 42:377-387. [PMID: 32390164 PMCID: PMC7576892 DOI: 10.1111/ics.12626] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2019] [Accepted: 04/27/2020] [Indexed: 12/13/2022]
Abstract
Objective Tyrosinase is the rate‐limiting enzyme in melanogenesis. Thiamidol is the most potent inhibitor of human tyrosinase out of 50 000 tested compounds. In clinical studies, it was shown to improve facial hyperpigmentation, post‐inflammatory hyperpigmentation and age spots significantly. To identify the optimal number of daily Thiamidol applications, we conducted a split‐face study comparing the efficacy and tolerability of four‐times with two‐times daily application. Subsequently, we evaluated the efficacy and tolerability of a typical face care regimen containing Thiamidol in a real‐world study. Methods The split‐face study was double‐blind, randomized, controlled, including two Thiamidol containing products (serum and day care SPF 30). The serum was applied twice daily on one half of the face and the day care SPF30 twice‐daily on the whole face. The real‐world study was open‐label, observational, including three Thiamidol containing products (day care SPF 30 in the morning, serum and night care in the evening). In both studies, subjects with mild‐to‐moderate facial hyperpigmentation applied the products over 12 weeks. Assessments included clinical and subjective grading of hyperpigmentation, skin condition, hemi‐/modified MASI, chromameter and clinical photography. Results In the split‐face study (n = 34), hyperpigmentation, skin roughness and hMASI improved all significantly (P < 0.001) versus baseline, with first visible results after two weeks of twice‐daily application. The four‐times daily application led to significant improvement versus the two‐times daily application. In the real‐world study (n = 83), all evaluated parameters, including skin condition and chromametry (n = 30), improved significantly (P < 0.001) in comparison with baseline and the corresponding preceding visits. The subjects judged the cosmetic properties of the products positively. In both studies, the products were well tolerated. Conclusion Four‐times daily Thiamidol improves facial hyperpigmentation significantly more than two‐times daily and is well tolerated by the subjects. The real‐world study with a typical face care regimen containing Thiamidol shows improvement of facial hyperpigmentation and confirms tolerability. Furthermore, the data provide evidence for the suitability of this three‐product Thiamidol regimen for day‐to‐day life.
Collapse
Affiliation(s)
- W G Philipp-Dormston
- Hautzentrum Köln, Schillingsrotter Str. 39-41, Köln, 50996, Germany.,Faculty of Health, University Witten/Herdecke, Witten, 58455, Germany
| | - A Vila Echagüe
- Centro de Referencia en Tratamiento Laser, Av. Del Libertador 662, Piso 17, depto. 42, Buenos Aires, Argentina
| | | | - J Riedel
- BDF Argentina, Av Triunvirato 2902, Buenos Aires, C1427 AAP CABA, Argentina
| | - A Filbry
- BDF Argentina, Av Triunvirato 2902, Buenos Aires, C1427 AAP CABA, Argentina
| | - K Warnke
- BDF Argentina, Av Triunvirato 2902, Buenos Aires, C1427 AAP CABA, Argentina
| | - C Lofrano
- Beiersdorf AG, Unnastrasse 48, Hamburg, 20245, Germany
| | - D Roggenkamp
- BDF Argentina, Av Triunvirato 2902, Buenos Aires, C1427 AAP CABA, Argentina
| | - G Nippel
- BDF Argentina, Av Triunvirato 2902, Buenos Aires, C1427 AAP CABA, Argentina
| |
Collapse
|
19
|
Saechan C, Nguyen UH, Wang Z, Sugimoto S, Yamano Y, Matsunami K, Otsuka H, Phan GM, Pham VH, Tipmanee V, Kaewsrichan J. Potency of bisresorcinol from Heliciopsis terminalis on skin aging: in vitro bioactivities and molecular interactions. PeerJ 2021; 9:e11618. [PMID: 34221723 PMCID: PMC8231342 DOI: 10.7717/peerj.11618] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2021] [Accepted: 05/25/2021] [Indexed: 12/18/2022] Open
Abstract
Background A bisresorcinol was isolated as the main constituent of Heliciopsis terminalis’s trunk (Proteaceae). Recently, resorcinol is applied as an active whitening agent in various cosmetic products. Because of the structural mimic to resorcinol, benefits of the bisresorcinol as an aging-enzyme antagonist were demonstrated in this study. Methods The bisresorcinol was purified from the crude ethanolic extract of H. terminalis’s trunk by solvent extraction and preparative chromatography, respectively. Inhibitory activity on collagenase, elastase, and tyrosinase of the compound was investigated by using a different spectroscopic technique. Molecular docking was carried out to predict possible interactions of the substance around the enzyme active sites. Results The IC50 values on collagenase of the bisresorcinol and caffeic acid were 156.7 ± 0.7 and 308.9 ± 1.6 µmole L−1, respectively. For elastase activity, the IC50 of 33.2 ± 0.5 and 34.3 ± 0.3 µmole L−1 was respectively determined for the bisresorcinol and ursolic acid. The bisresorcinol was inhibitory to tyrosinase by exhibiting the IC50 of 22.8 µmole L−1, and that of 78.4 µmole L−1 was present for β-arbutin. The bisresorcinol bound to collagenase, elastase, and tyrosinase with the respective binding energies of −5.89, −5.69, and −6.57 kcal mol−1. These binding energies were in the same ranges of tested inhibitors. The aromatic phenol groups in the structure were responsible for principle as well as supporting binding interactions with enzymes. Hydrogen binding due to hydroxyl groups and π-related attractive forces from an aromatic ring(s) provided binding versatility to bisresorcinol. Conclusion The bisresorcinol purified from H. terminalis might be useful for inclusion in cosmetic products as an aging-enzyme antagonist.
Collapse
Affiliation(s)
- Charinrat Saechan
- Department of Pharmaceutical Chemistry and Drug Delivery System Excellence Center, Faculty of Pharmaceutical Sciences, Prince of Songkla University, Songkhla, Thailand
| | - Uyen Hoang Nguyen
- Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
| | - Zhichao Wang
- Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
| | - Sachiko Sugimoto
- Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
| | - Yoshi Yamano
- Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
| | - Katsuyoshi Matsunami
- Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
| | - Hideaki Otsuka
- Faculty of Pharmacy, Yasuda Women's University, Hiroshima, Japan
| | - Giang Minh Phan
- Faculty of Chemistry, VNU University of Science, Vietnam National University, Hanoi, Vietnam
| | - Viet Hung Pham
- Research Center for Environmental Technology and Sustainable Development, VNU University of Science, Vietnam National University, Hanoi, Vietnam
| | - Varomyalin Tipmanee
- Department of Biomedical Sciences and Biomedical Engineering, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand
| | - Jasadee Kaewsrichan
- Department of Pharmaceutical Chemistry and Drug Delivery System Excellence Center, Faculty of Pharmaceutical Sciences, Prince of Songkla University, Songkhla, Thailand
| |
Collapse
|
20
|
Lima PB, Dias JAF, Cassiano DP, Esposito ACC, Miot LDB, Bagatin E, Miot HA. Efficacy and safety of topical isobutylamido thiazolyl resorcinol (Thiamidol) vs. 4% hydroquinone cream for facial melasma: an evaluator-blinded, randomized controlled trial. J Eur Acad Dermatol Venereol 2021; 35:1881-1887. [PMID: 33988887 DOI: 10.1111/jdv.17344] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2021] [Revised: 03/12/2021] [Accepted: 04/07/2021] [Indexed: 12/26/2022]
Abstract
BACKGROUND Melasma can be refractory to treatment, and relapses are frequent. Thiamidol is a new potent tyrosinase inhibitor that has been found effective as a cosmeceutical for the depigmenting of melasma. OBJECTIVE This study compared the efficacy and tolerability of topical 0.2% Thiamidol vs. 4% hydroquinone for facial melasma. METHODS Fifty women with facial melasma participated in a randomized, evaluator-blinded, controlled study from September through November 2020. Patients were randomly assigned to apply a double layer of 0.2% Thiamidol twice a day or 4% hydroquinone cream at bedtime, for 90 days. Both groups received tinted sunscreen (sun protection factor 60, PPD 20). The primary outcome was the change from the baseline Modified Melasma Area Seve:rity Index (mMASI) score. Secondary outcomes were improvements in the patients' quality of life [Melasma Quality of Life Index (MELASQoL)], colourimetry, and Global Aesthetic Improvement Scale (GAIS) evaluation. RESULTS One participant, from the hydroquinone group, did not complete the study (unrelated to adverse effects). The mean (SD) age of the participants was 43 (6) years, and 86% were phototypes III-IV. Both groups exhibited a reduction in mMASI, MELASQoL, and colour contrast scores (P < 0.01). The mean [95% confidence interval (CI 95%)] reductions of the mMASI scores were 43% (35-50%) for Thiamidol and 33% (23-42%) for hydroquinone. There was no difference between the groups in the reductions in mMASI, MELASQoL, colourimetric contrast and GAIS scores (P ≥ 0.09). The GAIS analysis resulted in an improvement of 84% (CI: 95% 67-97%) for participants in the Thiamidol group and 74% (CI: 95% 61-93%) for those in the hydroquinone group. There were only mild adverse effects in the Thiamidol group, but allergic contact dermatitis was evidenced in two (8%) participants. CONCLUSION The melasma improvement achieved using 0.2% Thiamidol did not differ from that of 4% hydroquinone cream. Thiamidol can be considered a suitable option for melasma patients with poor tolerability or treatment failure with hydroquinone.
Collapse
Affiliation(s)
- P B Lima
- Departamento de Dermatologia e Radioterapia, FMB-Unesp, Botucatu, Brazil
| | - J A F Dias
- Departamento de Dermatologia e Radioterapia, FMB-Unesp, Botucatu, Brazil
| | - D P Cassiano
- Departamento de Dermatologia, UNIFESP, São Paulo, Brazil
| | - A C C Esposito
- Departamento de Dermatologia e Radioterapia, FMB-Unesp, Botucatu, Brazil
| | - L D B Miot
- Departamento de Dermatologia e Radioterapia, FMB-Unesp, Botucatu, Brazil
| | - E Bagatin
- Departamento de Dermatologia, UNIFESP, São Paulo, Brazil
| | - H A Miot
- Departamento de Dermatologia e Radioterapia, FMB-Unesp, Botucatu, Brazil
| |
Collapse
|
21
|
Lee S, Choi H, Park Y, Jung HJ, Ullah S, Choi I, Kang D, Park C, Ryu IY, Jeong Y, Hwang Y, Hong S, Chun P, Moon HR. Urolithin and Reduced Urolithin Derivatives as Potent Inhibitors of Tyrosinase and Melanogenesis: Importance of the 4-Substituted Resorcinol Moiety. Int J Mol Sci 2021; 22:ijms22115616. [PMID: 34070680 PMCID: PMC8199067 DOI: 10.3390/ijms22115616] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2021] [Revised: 05/17/2021] [Accepted: 05/22/2021] [Indexed: 12/17/2022] Open
Abstract
We previously reported (E)-β-phenyl-α,β-unsaturated carbonyl scaffold ((E)-PUSC) played an important role in showing high tyrosinase inhibitory activity and that derivatives with a 4-substituted resorcinol moiety as the β-phenyl group of the scaffold resulted in the greatest tyrosinase inhibitory activity. To examine whether the 4-substituted resorcinol moiety could impart tyrosinase inhibitory activity in the absence of the α,β-unsaturated carbonyl moiety of the (E)-PUSC scaffold, 10 urolithin derivatives were synthesized. To obtain more candidate samples, the lactone ring in synthesized urolithins was reduced to produce nine reduced urolithins. Compounds 1c (IC50 = 18.09 ± 0.25 μM), 1h (IC50 = 4.14 ± 0.10 μM), and 2a (IC50 = 15.69 ± 0.40 μM) had greater mushroom tyrosinase-inhibitory activities than kojic acid (KA) (IC50 = 48.62 ± 3.38 μM). The SAR results suggest that the 4-substituted resorcinol motif makes an important contribution to tyrosinase inhibition. To investigate whether these compounds bind to human tyrosinase, a human tyrosinase homology model was developed. Docking simulations with mushroom and human tyrosinases showed that 1c, 1h, and 2a bind to the active site of both tyrosinases with higher binding affinities than KA. Pharmacophore analyses showed that two hydroxyl groups of the 4-substituted resorcinol entity act as hydrogen bond donors in both mushroom and human tyrosinases. Kinetic analyses indicated that these compounds were all competitive inhibitors. Compound 2a inhibited cellular tyrosinase activity and melanogenesis in α-MSH plus IBMX-stimulated B16F10 melanoma cells more strongly than KA. These results suggest that 2a is a promising candidate for the treatment of skin pigment disorders, and show the 4-substituted resorcinol entity importantly contributes to tyrosinase inhibition.
Collapse
Affiliation(s)
- Sanggwon Lee
- College of Pharmacy, Pusan National University, Busan 46241, Korea; (S.L.); (H.C.); (Y.P.); (H.J.J.); (I.C.); (D.K.); (C.P.); (I.Y.R.); (Y.J.); (Y.H.); (S.H.)
| | - Heejeong Choi
- College of Pharmacy, Pusan National University, Busan 46241, Korea; (S.L.); (H.C.); (Y.P.); (H.J.J.); (I.C.); (D.K.); (C.P.); (I.Y.R.); (Y.J.); (Y.H.); (S.H.)
| | - Yujin Park
- College of Pharmacy, Pusan National University, Busan 46241, Korea; (S.L.); (H.C.); (Y.P.); (H.J.J.); (I.C.); (D.K.); (C.P.); (I.Y.R.); (Y.J.); (Y.H.); (S.H.)
| | - Hee Jin Jung
- College of Pharmacy, Pusan National University, Busan 46241, Korea; (S.L.); (H.C.); (Y.P.); (H.J.J.); (I.C.); (D.K.); (C.P.); (I.Y.R.); (Y.J.); (Y.H.); (S.H.)
| | - Sultan Ullah
- Department of Molecular Medicine, The Scripps Research Institute, Jupiter, FL 33458, USA;
| | - Inkyu Choi
- College of Pharmacy, Pusan National University, Busan 46241, Korea; (S.L.); (H.C.); (Y.P.); (H.J.J.); (I.C.); (D.K.); (C.P.); (I.Y.R.); (Y.J.); (Y.H.); (S.H.)
| | - Dongwan Kang
- College of Pharmacy, Pusan National University, Busan 46241, Korea; (S.L.); (H.C.); (Y.P.); (H.J.J.); (I.C.); (D.K.); (C.P.); (I.Y.R.); (Y.J.); (Y.H.); (S.H.)
| | - Chaeun Park
- College of Pharmacy, Pusan National University, Busan 46241, Korea; (S.L.); (H.C.); (Y.P.); (H.J.J.); (I.C.); (D.K.); (C.P.); (I.Y.R.); (Y.J.); (Y.H.); (S.H.)
| | - Il Young Ryu
- College of Pharmacy, Pusan National University, Busan 46241, Korea; (S.L.); (H.C.); (Y.P.); (H.J.J.); (I.C.); (D.K.); (C.P.); (I.Y.R.); (Y.J.); (Y.H.); (S.H.)
| | - Yeongmu Jeong
- College of Pharmacy, Pusan National University, Busan 46241, Korea; (S.L.); (H.C.); (Y.P.); (H.J.J.); (I.C.); (D.K.); (C.P.); (I.Y.R.); (Y.J.); (Y.H.); (S.H.)
| | - YeJi Hwang
- College of Pharmacy, Pusan National University, Busan 46241, Korea; (S.L.); (H.C.); (Y.P.); (H.J.J.); (I.C.); (D.K.); (C.P.); (I.Y.R.); (Y.J.); (Y.H.); (S.H.)
| | - Sojeong Hong
- College of Pharmacy, Pusan National University, Busan 46241, Korea; (S.L.); (H.C.); (Y.P.); (H.J.J.); (I.C.); (D.K.); (C.P.); (I.Y.R.); (Y.J.); (Y.H.); (S.H.)
| | - Pusoon Chun
- College of Pharmacy and Inje Institute of Pharmaceutical Sciences and Research, Inje University, Gimhae 50834, Korea;
| | - Hyung Ryong Moon
- College of Pharmacy, Pusan National University, Busan 46241, Korea; (S.L.); (H.C.); (Y.P.); (H.J.J.); (I.C.); (D.K.); (C.P.); (I.Y.R.); (Y.J.); (Y.H.); (S.H.)
- Correspondence: ; Tel.: +82-51-510-2815; Fax: +82-51-513-6754
| |
Collapse
|
22
|
Roggenkamp D, Dlova N, Mann T, Batzer J, Riedel J, Kausch M, Zoric I, Kolbe L. Effective reduction of post-inflammatory hyperpigmentation with the tyrosinase inhibitor isobutylamido-thiazolyl-resorcinol (Thiamidol). Int J Cosmet Sci 2021; 43:292-301. [PMID: 33559186 PMCID: PMC8251899 DOI: 10.1111/ics.12694] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2020] [Revised: 02/05/2021] [Accepted: 02/06/2021] [Indexed: 12/04/2022]
Abstract
Objective Post‐inflammatory hyperpigmentation (PIH) is a major cosmetic concern especially in individuals with darker skin complexion. Unfortunately, treatment with anti‐inflammatory ingredients alone does not prevent the development of hyperpigmented spots. Recently, isobutylamido‐thiazolyl‐resorcinol (Thiamidol) was described as a very potent inhibitor of human tyrosinase. The objective of this research was to investigate the potential of this compound to prevent PIH induced by epidermal wounding (suction blister) and related to acne. Methods Suction blister‐induced PIH was treated with a formulation containing Thiamidol or a vehicle for 3 months, and the changes in hyperpigmentation were monitored by spectroscopic measurements. The effect of skin care formulations containing Thiamidol on acne‐related PIH was investigated in two studies, a vehicle‐controlled, double‐blinded, randomized clinical study and a clinical observational study. Both studies had a duration of 3 months and included assessments such as clinical photography, clinical grading and melanin index measurements. Results Already after 2 weeks of treatment, suction blister sites treated with Thiamidol were significantly lighter than control sites and improved throughout the treatment period. Subjects´ self‐grading demonstrated that Thiamidol significantly improved the visibility of acne‐induced hyperpigmentation compared to the vehicle treatment. A skin care regimen with Thiamidol significantly improved acne‐related PIH over 12 weeks shown by Mexameter measurements, expert grading, self‐grading and clinical photography. Conclusion Thiamidol represents a safe and effective ingredient for cosmetic products against post‐inflammatory hyperpigmentation.
Collapse
Affiliation(s)
- Dennis Roggenkamp
- International Medical Management Eucerin, Beiersdorf AG, Hamburg, Germany
| | - Ncoza Dlova
- Nelson R Mandela School of Medicine, Durban, South Africa
| | - Tobias Mann
- Research & Development, Beiersdorf AG, Hamburg, Germany
| | - Jan Batzer
- Research & Development, Beiersdorf AG, Hamburg, Germany
| | - Julia Riedel
- Research & Development, Beiersdorf AG, Hamburg, Germany
| | | | - Ivica Zoric
- Research & Development, Beiersdorf AG, Hamburg, Germany
| | - Ludger Kolbe
- Research & Development, Beiersdorf AG, Hamburg, Germany
| |
Collapse
|
23
|
Ko SC, Lee SH. Protocatechuic Aldehyde Inhibits α-MSH-Induced Melanogenesis in B16F10 Melanoma Cells via PKA/CREB-Associated MITF Downregulation. Int J Mol Sci 2021; 22:ijms22083861. [PMID: 33917915 PMCID: PMC8068260 DOI: 10.3390/ijms22083861] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2021] [Revised: 04/06/2021] [Accepted: 04/08/2021] [Indexed: 11/16/2022] Open
Abstract
Protocatechuic aldehyde (PA) is a naturally occurring phenolic compound that is a potent inhibitor of mushroom tyrosinase. However, the molecular mechanisms of the anti-melanogenesis activity of PA have not yet been reported. The aim of the current study was to clarify the melanogenesis inhibitory effects of PA and its molecular mechanisms in murine melanoma cells (B16F10). We first predicted the 3D structure of tyrosinase and used a molecular docking algorithm to simulate binding between tyrosinase and PA. These molecular modeling studies calculated a binding energy of -527.42 kcal/mol and indicated that PA interacts with Cu400 and 401, Val283, and His263. Furthermore, PA significantly decreased α-MSH-induced intracellular tyrosinase activity and melanin content in a dose-dependent manner. PA also inhibited key melanogenic proteins such as tyrosinase, tyrosinase-related protein 1 (TRP-1), and TRP-2 in α-MSH-stimulated B16F10 cells. In addition, PA decreased MITF expression levels by inhibiting phosphorylation of cAMP response element-binding protein (CREB) and cAMP-dependent protein kinase A (PKA). These results demonstrate that PA can effectively suppress melanin synthesis in melanoma cells. Taken together, our results show that PA could serve as a potential inhibitor of melanogenesis, and hence could be explored as a possible skin-lightening agent.
Collapse
Affiliation(s)
- Seok-Chun Ko
- Department of Genetic Resources, National Marine Biodiversity Institute of Korea, Seocheon 33662, Korea;
| | - Seung-Hong Lee
- Department of Pharmaceutical Engineering and Medical Science, Soonchunhyang University, Asan 31538, Korea
- Correspondence: ; Tel.: +82-41-530-4980; Fax: +82-41-530-3085
| |
Collapse
|
24
|
Disphanurat W, Srisantithum B. Efficacy and safety of 0.15% isobutylamido thiazolyl resorcinol combined with hyaluronic acid vs 0.15% isobutylamido thiazolyl resorcinol or hyaluronic acid alone in melasma treatment: A randomized evaluator-blind trial. J Cosmet Dermatol 2021; 20:3563-3572. [PMID: 33638926 DOI: 10.1111/jocd.14031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2021] [Revised: 02/19/2021] [Accepted: 02/23/2021] [Indexed: 10/22/2022]
Abstract
BACKGROUND Melasma has a complex pathogenesis, and various aggravating factors contribute to its recalcitrance to treatments. A combination of isobutylamido thiazolyl resorcinol (ITR) and hyaluronic acid (HA) could increase melasma treatment efficacy. AIMS To compare the efficacy and safety of 0.15% ITR plus HA vs 0.15% ITR or HA alone in melasma treatment. METHODS Ninety-two patients received ITR 0.15% plus HA (n = 30), 0.15% ITR (n = 31), or HA (n = 31) along with broad-spectrum sunscreen application for 12 weeks. Treatment efficacy was determined using modified Melasma Area Severity Index (mMASI), average melanin and melanin variation with Antera3D® , and safety based on transepidermal water loss. RESULTS Compared with the HA group, the ITR+HA group showed significantly reduced mMASI at weeks 4, 8, and 12 (p = 0.026, 0.015, and 0.001, respectively), whereas the ITR group showed a significant reduction at week 12 (p = 0.027). There was no significant difference in the mMASI or average melanin level between the ITR+HA and ITR groups. Melanin variation was significantly lower in the ITR+HA group than in the ITR group at weeks 4, 8, and 12 (p = 0.027, 0.019, and 0.023, respectively). CONCLUSIONS The combination of 0.15% ITR and 0.15% ITR+HA effectively reduced melasma severity. HA could synergistically improve melasma homogeneity.
Collapse
Affiliation(s)
- Wareeporn Disphanurat
- Division of Dermatology, Department of Medicine, Thammasat University, Pathum Thani, Thailand
| | - Benjaporn Srisantithum
- Division of Dermatology, Department of Medicine, Thammasat University, Pathum Thani, Thailand
| |
Collapse
|
25
|
Roulier B, Pérès B, Haudecoeur R. Advances in the Design of Genuine Human Tyrosinase Inhibitors for Targeting Melanogenesis and Related Pigmentations. J Med Chem 2020; 63:13428-13443. [PMID: 32787103 DOI: 10.1021/acs.jmedchem.0c00994] [Citation(s) in RCA: 64] [Impact Index Per Article: 16.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
Human tyrosinase (hsTYR) is the key enzyme ensuring the conversion of l-tyrosine to dopaquinone, thereby initiating melanin synthesis, i.e., melanogenesis. Although the protein has long been familiar, knowledge about its three-dimensional structure and efficient overexpression protocols emerged only recently. Consequently, for decades medicinal chemistry studies aiming at developing skin depigmenting agents relied almost exclusively on biological assays performed using mushroom tyrosinase (abTYR), producing a plethoric literature, often of little useful purpose. Indeed, several recent reports have pointed out spectacular differences in terms of interaction patterns and inhibition values between hsTYR and abTYR, including for widely used standard tyrosinase inhibitors. In this review, we summarize the last developments regarding the potential role of hsTYR in human pathologies, the advances in recombinant expression systems and structural data retrieving, and the pioneer generation of true hsTYR inhibitors. Finally, we present suggestions for the design of future inhibitors of this highly attractive target in pharmacology and dermocosmetics.
Collapse
Affiliation(s)
- Brayan Roulier
- Département de Pharmacochimie Moléculaire (DPM), UMR 5063, Université Grenoble Alpes, 38041 Grenoble, France
| | - Basile Pérès
- Département de Pharmacochimie Moléculaire (DPM), UMR 5063, Université Grenoble Alpes, 38041 Grenoble, France
| | - Romain Haudecoeur
- Département de Pharmacochimie Moléculaire (DPM), UMR 5063, Université Grenoble Alpes, 38041 Grenoble, France
| |
Collapse
|
26
|
Catalano M, Bassi G, Rotondi G, Khettabi L, Dichiara M, Murer P, Scheuermann J, Soler-Lopez M, Neri D. Discovery, affinity maturation and multimerization of small molecule ligands against human tyrosinase and tyrosinase-related protein 1. RSC Med Chem 2020; 12:363-369. [PMID: 34041485 PMCID: PMC8130610 DOI: 10.1039/d0md00310g] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
Human tyrosinase (hTYR) and tyrosinase-related protein 1 (hTYRP1) are closely-related enzymes involved in the synthesis of melanin, which are selectively expressed in melanocytes and, in a pathological context, in melanoma lesions. We used a previously described tyrosinase inhibitor (Thiamidol™) and DNA-encoded library technology for the discovery of novel hTYR and hTYRP1 ligands, that could be used as vehicles for melanoma targeting. Performing de novo selections with DNA-encoded libraries, we discovered novel ligands capable of binding to both hTYR and hTYRP1. More potent ligands were obtained by multimerizing Thiamidol™ moieties, leading to homotetrameric structures that avidly bound to melanoma cells, as revealed by flow cytometry. These findings suggest that melanoma lesions may, in the future, be targeted not only by monoclonal antibody reagents but also by small organic ligands. A series of different strategies were oriented toward the discovery of small molecule ligands binding to the human version of tyrosinase (hTYR) and tyrosinase-related protein 1 (hTYRP1), which may represent the basis for novel treatments of melanoma.![]()
Collapse
Affiliation(s)
- Marco Catalano
- Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH Zürich) Vladimir-Prelog-Weg 4 CH-8093 Zürich Switzerland
| | - Gabriele Bassi
- Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH Zürich) Vladimir-Prelog-Weg 4 CH-8093 Zürich Switzerland
| | - Giulia Rotondi
- Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH Zürich) Vladimir-Prelog-Weg 4 CH-8093 Zürich Switzerland .,Dipartimento di Chimica e Tecnologie del Farmaco, Sapienza University of Rome P.le A. Moro 5 00185 Rome Italy
| | - Lyna Khettabi
- Structural Biology Group, European Synchrotron Radiation Facility 71 Avenue des Martyrs 38000 Grenoble France.,CNRS, DCM, Université Grenoble Alpes 38000 Grenoble France
| | - Maria Dichiara
- Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH Zürich) Vladimir-Prelog-Weg 4 CH-8093 Zürich Switzerland
| | - Patrizia Murer
- Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH Zürich) Vladimir-Prelog-Weg 4 CH-8093 Zürich Switzerland
| | - Jörg Scheuermann
- Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH Zürich) Vladimir-Prelog-Weg 4 CH-8093 Zürich Switzerland
| | - Montserrat Soler-Lopez
- Structural Biology Group, European Synchrotron Radiation Facility 71 Avenue des Martyrs 38000 Grenoble France
| | - Dario Neri
- Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH Zürich) Vladimir-Prelog-Weg 4 CH-8093 Zürich Switzerland
| |
Collapse
|
27
|
Vachiramon V, Kositkuljorn C, Leerunyakul K, Chanprapaph K. Isobutylamido thiazolyl resorcinol for prevention of UVB-induced hyperpigmentation. J Cosmet Dermatol 2020; 20:987-992. [PMID: 32757247 DOI: 10.1111/jocd.13615] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2020] [Revised: 07/05/2020] [Accepted: 07/07/2020] [Indexed: 12/22/2022]
Abstract
BACKGROUND Isobutylamido thiazolyl resorcinol (ITR, Thiamidol® ) has been proposed as a potent tyrosinase inhibitor. A formulation containing ITR has recently shown promising efficacy for the treatment of some hyperpigmentary conditions. OBJECTIVES This study aimed to evaluate the efficacy and safety of ITR in the prevention of ultraviolet (UV)-induced hyperpigmentation in human skin. MATERIALS AND METHODS We performed a randomized, single-blinded, pilot study in 30 healthy participants. One arm was randomly assigned to receive an ITR-containing product for three weeks. Three hyperpigmented spots were induced by UVB irradiation on both arms after 3 weeks of ITR application. Outcome evaluations included measuring mean lightness index (*L) obtained by colorimeter, hyperpigmentation scores by visual analog scale (VAS), and adverse effects. RESULTS Both experimental sides showed no significant difference in terms of skin lightening after ITR application. However, the ITR-treated sides showed a statistically significant lower mean lightness index compared to control after an induction with UVB. In addition, the ITR-treated sides had an earlier improvement and resumed the normal skin color after 3 weeks post-UVB induction. A clinical evaluation by a blinded nontreating physician and subjects was more favorable on the ITR-treated side than the control side (P < .05). No significant side effect was noted. CONCLUSIONS ITR is an effective agent in the prevention of pigmentary change from UVB irradiation and may serve as a promising agent for preventing other hyperpigmentary conditions.
Collapse
Affiliation(s)
- Vasanop Vachiramon
- Division of Dermatology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
| | - Chaninan Kositkuljorn
- Division of Dermatology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
| | - Kanchana Leerunyakul
- Division of Dermatology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
| | - Kumutnart Chanprapaph
- Division of Dermatology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
| |
Collapse
|
28
|
Atiya A, Salim MA, Sinha BN, Ranjan Lal U. Two new anticancer phenolic derivatives from leaves of Piper betle Linn. Nat Prod Res 2020; 35:5021-5029. [PMID: 32375527 DOI: 10.1080/14786419.2020.1762186] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
In this study, phytochemical analyses of the chloroform extract of Piper betle L. var. haldia and maghai, Piperaceae, leaves led to the isolation of two new phenolic derivatives: 1-n-decanoyl hydroxy-benzoic acid/1-n-decanoyl phenol (H2) and 3-butylphenol (M1) on the basis of spectroscopic data 1D NMR (1H, 13C) and 2D NMR (1H - 1H COSY, HMBC) as well as ESI-MS, FT-IR and HR-ESI-MS analyses. Compounds H2 and M1 showed excellent antioxidant DPPH free radical scavenging activity with IC50 values of 10.66 μ/mL and 13.65 μg/mL compared to ascorbic acid as a standard antioxidant with an IC50 value of 2.52 μg/mL. Evaluation of cytotoxic activity against two human oral cancer cell lines (SCC-40 and SCC-29B) showed significant effect with GI50 values of 24.08 and 33.08 μg/mL for compound H2 and 35.03 and 47.06 μg/mL for compound M1, compared to Doxorubicin® as a standard cytotoxic drug with GI50 value of < 10 μg/mL.
Collapse
Affiliation(s)
- Akhtar Atiya
- Department of Pharmacognosy and Phytochemistry, College of pharmacy, King Khalid University (KKU), Abha, Saudi Arabia.,Division of Pharmacognosy and Phytochemistry, Department of Pharmaceutical Sciences and Technology, Birla institute of Technology, Ranchi, Jharkhand, India
| | - Mohammed Azhar Salim
- Department of Chemistry, Aligarh Muslim University, (AMU), Aligarh, Uttar Pradesh, India
| | - Barij Nayan Sinha
- Division of Medicinal Chemistry, Department of Pharmaceutical Sciences and Technology, Birla Institute of Technology, Ranchi, Jharkhand, India
| | - Uma Ranjan Lal
- Division of Pharmacognosy and Phytochemistry, Department of Pharmaceutical Sciences and Technology, Birla institute of Technology, Ranchi, Jharkhand, India
| |
Collapse
|
29
|
Zolghadri S, Bahrami A, Hassan Khan MT, Munoz-Munoz J, Garcia-Molina F, Garcia-Canovas F, Saboury AA. A comprehensive review on tyrosinase inhibitors. J Enzyme Inhib Med Chem 2019; 34:279-309. [PMID: 30734608 PMCID: PMC6327992 DOI: 10.1080/14756366.2018.1545767] [Citation(s) in RCA: 486] [Impact Index Per Article: 97.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2018] [Revised: 11/04/2018] [Accepted: 11/05/2018] [Indexed: 12/17/2022] Open
Abstract
Tyrosinase is a multi-copper enzyme which is widely distributed in different organisms and plays an important role in the melanogenesis and enzymatic browning. Therefore, its inhibitors can be attractive in cosmetics and medicinal industries as depigmentation agents and also in food and agriculture industries as antibrowning compounds. For this purpose, many natural, semi-synthetic and synthetic inhibitors have been developed by different screening methods to date. This review has focused on the tyrosinase inhibitors discovered from all sources and biochemically characterised in the last four decades.
Collapse
Affiliation(s)
- Samaneh Zolghadri
- Department of Biology, Jahrom Branch, Islamic Azad University, Jahrom, Iran
| | - Asieh Bahrami
- Department of Biology, Jahrom Branch, Islamic Azad University, Jahrom, Iran
| | | | - J. Munoz-Munoz
- Group of Microbiology, Department of Applied Sciences, Northumbria University at Newcastle, Newcastle Upon Tyne, UK
| | - F. Garcia-Molina
- GENZ-Group of Research on Enzymology, Department of Biochemistry and Molecular Biology-A, Regional Campus of International Excellence "Campus Mare Nostrum", University of Murcia, Espinardo, Murcia, Spain
| | - F. Garcia-Canovas
- GENZ-Group of Research on Enzymology, Department of Biochemistry and Molecular Biology-A, Regional Campus of International Excellence "Campus Mare Nostrum", University of Murcia, Espinardo, Murcia, Spain
| | - Ali Akbar Saboury
- Institute of Biochemistry and Biophysics, University of Tehran, Tehran, Iran
| |
Collapse
|
30
|
Effective Tyrosinase Inhibition by Thiamidol Results in Significant Improvement of Mild to Moderate Melasma. J Invest Dermatol 2019; 139:1691-1698.e6. [PMID: 30825454 DOI: 10.1016/j.jid.2019.02.013] [Citation(s) in RCA: 35] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2018] [Revised: 02/05/2019] [Accepted: 02/11/2019] [Indexed: 10/27/2022]
Abstract
Melasma is a pigmentary disorder characterized by hyperpigmented patchy skin in sun-exposed areas, especially the face. Treatment of melasma can be challenging because long-term therapy is required, reoccurrence is common, and existing therapies are insufficient and unsatisfactory. To investigate new treatment options, we performed an exploratory double-blinded, randomized split-face study to assess the efficacy of the tyrosinase inhibitor Thiamidol compared to hydroquinone in women with mild to moderate melasma. After 12 weeks, modified Melasma Area and Severity Index scores significantly improved on both the Thiamidol-treated and the hydroquinone-treated sides of the face. Additionally, Thiamidol treatment improved modified Melasma Area and Severity Index scores significantly better than hydroquinone, and more subjects improved following treatment with Thiamidol (79%) compared with hydroquinone (61%). During treatment, no subjects displayed worsening of modified Melasma Area and Severity Index scores on the Thiamidol-treated side, while approximately 10% of the subjects showed a worsening of modified Melasma Area and Severity Index scores on the hydroquinone-treated side. All subjects routinely used sunscreens and consistent results were obtained in low and in high UV ambient conditions. Subjects rated the efficacy of the Thiamidol formulation significantly better with regard to overall decreased intensity of dark spots and their overall appearance throughout the study. Thiamidol was well-tolerated and well-perceived and represents an effective agent to reduce hyperpigmentation.
Collapse
|
31
|
Skin Pigmentation: Is the Control of Melanogenesis a Target within Reach? Int J Mol Sci 2018; 19:ijms19124040. [PMID: 30558112 PMCID: PMC6320957 DOI: 10.3390/ijms19124040] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2018] [Accepted: 12/11/2018] [Indexed: 12/12/2022] Open
|
32
|
Schlich M, Fornasier M, Nieddu M, Sinico C, Murgia S, Rescigno A. 3-hydroxycoumarin loaded vesicles for recombinant human tyrosinase inhibition in topical applications. Colloids Surf B Biointerfaces 2018; 171:675-681. [DOI: 10.1016/j.colsurfb.2018.08.008] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2018] [Revised: 08/03/2018] [Accepted: 08/07/2018] [Indexed: 10/28/2022]
|
33
|
Micillo R, Sirés-Campos J, García-Borrón JC, Panzella L, Napolitano A, Olivares C. Conjugation with Dihydrolipoic Acid Imparts Caffeic Acid Ester Potent Inhibitory Effect on Dopa Oxidase Activity of Human Tyrosinase. Int J Mol Sci 2018; 19:E2156. [PMID: 30042336 PMCID: PMC6121902 DOI: 10.3390/ijms19082156] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2018] [Revised: 07/18/2018] [Accepted: 07/20/2018] [Indexed: 12/18/2022] Open
Abstract
Caffeic acid derivatives represent promising lead compounds in the search for tyrosinase inhibitors to be used in the treatment of skin local hyperpigmentation associated to an overproduction or accumulation of melanin. We recently reported the marked inhibitory activity of a conjugate of caffeic acid with dihydrolipoic acid, 2-S-lipoylcaffeic acid (LCA), on the tyrosine hydroxylase (TH) and dopa oxidase (DO) activities of mushroom tyrosinase. In the present study, we evaluated a more lipophilic derivative, 2-S-lipoyl caffeic acid methyl ester (LCAME), as an inhibitor of tyrosinase from human melanoma cells. Preliminary analysis of the effects of LCAME on mushroom tyrosinase indicated more potent inhibitory effects on either enzyme activities (IC50 = 0.05 ± 0.01 μM for DO and 0.83 ± 0.09 μM for TH) compared with LCA and the reference compound kojic acid. The inhibition of DO of human tyrosinase was effective (Ki = 34.7 ± 1.1 μM) as well, while the action on TH was weaker. Lineweaver⁻Burk analyses indicated a competitive inhibitor mechanism. LCAME was not substrate of tyrosinase and proved nontoxic at concentrations up to 50 μM. No alteration of basal tyrosinase expression was observed after 24 h treatment of human melanoma cells with the inhibitor, but preliminary evidence suggested LCAME might impair the induction of tyrosinase expression in cells stimulated with α-melanocyte-stimulating hormone. All these data point to this compound as a valuable candidate for further trials toward its use as a skin depigmenting agent. They also highlight the differential effects of tyrosinase inhibitors on the human and mushroom enzymes.
Collapse
Affiliation(s)
- Raffaella Micillo
- Department of Chemical Sciences, University of Naples Federico II, Via Cintia 4, I-80126 Naples, Italy.
| | - Julia Sirés-Campos
- Department of Biochemistry and Molecular Biology, School of Medicine, University of Murcia and Instituto Murciano de Investigación Biosanitaria (IMIB), 30120 El Palmar, Spain.
| | - José Carlos García-Borrón
- Department of Biochemistry and Molecular Biology, School of Medicine, University of Murcia and Instituto Murciano de Investigación Biosanitaria (IMIB), 30120 El Palmar, Spain.
| | - Lucia Panzella
- Department of Chemical Sciences, University of Naples Federico II, Via Cintia 4, I-80126 Naples, Italy.
| | - Alessandra Napolitano
- Department of Chemical Sciences, University of Naples Federico II, Via Cintia 4, I-80126 Naples, Italy.
| | - Conchi Olivares
- Department of Biochemistry and Molecular Biology, School of Medicine, University of Murcia and Instituto Murciano de Investigación Biosanitaria (IMIB), 30120 El Palmar, Spain.
| |
Collapse
|